Exhibit 99.1 CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates IRVINE, Calif., November 14, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today reported financial results for the third quarter ended September 30, 2025, and provided business updates. "I am proud of the meaningful progress ...